TY - JOUR
T1 - Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries
T2 - a systematic analysis from the global burden of disease study 2019
AU - Danpanichkul, Pojsakorn
AU - Suparan, Kanokphong
AU - Dutta, Priyata
AU - Kaeosri, Chuthathip
AU - Sukphutanan, Banthoon
AU - Pang, Yanfang
AU - Kulthamrongsri, Narathorn
AU - Jaisa-aad, Methasit
AU - Ng, Cheng Han
AU - Teng, Margaret
AU - Nakano, Masahito
AU - Morishita, Asahiro
AU - Alkhouri, Naim
AU - Yang, Ju Dong
AU - Chen, Vincent L.
AU - Kim, Donghee
AU - Fallon, Michael B.
AU - Diaz, Luis Antonio
AU - Arab, Juan Pablo
AU - Mantzoros, Christos S.
AU - Noureddin, Mazen
AU - Lazarus, Jeffrey V.
AU - Wijarnpreecha, Karn
N1 - Copyright © 2024 Elsevier Inc. All rights reserved.
PY - 2024/9
Y1 - 2024/9
N2 - Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiometabolic conditions affect populations across economic strata. Nevertheless, there are limited epidemiological studies addressing these diseases in low (LICs) and lower-middle-income countries (lower MICs). Therefore, an analysis of the trend of MASLD and cardiometabolic conditions in these countries is necessary. Methods: From 2000 to 2019, jointpoint regression analysis was employed to calculate the prevalence, mortality, and disability-adjusted life years (DALYs) for cardiometabolic conditions including MASLD, type 2 diabetes mellitus (T2DM), dyslipidemia (DLP), hypertension (HTN), obesity, peripheral artery disease (PAD), atrial fibrillation and flutter (AF/AFL), ischemic heart disease (IHD), stroke, and chronic kidney disease from HTN and T2DM, in LICs and lower MICs (according to the World Bank Classification 2019) using the Global Burden of Disease 2019 data. Results: Among the eleven cardiometabolic conditions, MASLD (533.65 million), T2DM (162.96 million), and IHD (76.81 million) had the highest prevalence in LICs and Lower MICs in 2019. MASLD represented the largest proportion of global prevalence in these countries (43 %). From 2000 to 2019, mortality in LICs and lower MICs increased in all cardiometabolic conditions, with obesity-related mortality having the highest increase (+134 %). During this timeframe, there were increased age-standardized death rates (ASDR) from obesity, PAD, and AF/AFL. From all conditions, the DALYs-to-prevalence ratio was higher in LICs and lower MICs than the global average. Conclusion: The burden of MASLD and cardiometabolic conditions is increasing worldwide, with LICs and lower MICs experiencing higher (DALYs) disability per prevalence. As these conditions are preventable, counteracting these trends requires not only the modification of ongoing actions but also the strategizing of immediate interventions.
AB - Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiometabolic conditions affect populations across economic strata. Nevertheless, there are limited epidemiological studies addressing these diseases in low (LICs) and lower-middle-income countries (lower MICs). Therefore, an analysis of the trend of MASLD and cardiometabolic conditions in these countries is necessary. Methods: From 2000 to 2019, jointpoint regression analysis was employed to calculate the prevalence, mortality, and disability-adjusted life years (DALYs) for cardiometabolic conditions including MASLD, type 2 diabetes mellitus (T2DM), dyslipidemia (DLP), hypertension (HTN), obesity, peripheral artery disease (PAD), atrial fibrillation and flutter (AF/AFL), ischemic heart disease (IHD), stroke, and chronic kidney disease from HTN and T2DM, in LICs and lower MICs (according to the World Bank Classification 2019) using the Global Burden of Disease 2019 data. Results: Among the eleven cardiometabolic conditions, MASLD (533.65 million), T2DM (162.96 million), and IHD (76.81 million) had the highest prevalence in LICs and Lower MICs in 2019. MASLD represented the largest proportion of global prevalence in these countries (43 %). From 2000 to 2019, mortality in LICs and lower MICs increased in all cardiometabolic conditions, with obesity-related mortality having the highest increase (+134 %). During this timeframe, there were increased age-standardized death rates (ASDR) from obesity, PAD, and AF/AFL. From all conditions, the DALYs-to-prevalence ratio was higher in LICs and lower MICs than the global average. Conclusion: The burden of MASLD and cardiometabolic conditions is increasing worldwide, with LICs and lower MICs experiencing higher (DALYs) disability per prevalence. As these conditions are preventable, counteracting these trends requires not only the modification of ongoing actions but also the strategizing of immediate interventions.
KW - Disparity
KW - Epidemiology
KW - Liver disease
KW - MASLD
KW - Metabolic syndrome
KW - NAFLD
KW - Non-alcoholic fatty liver disease
UR - http://www.scopus.com/inward/record.url?scp=85197032712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85197032712&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2024.155958
DO - 10.1016/j.metabol.2024.155958
M3 - Article
C2 - 38942169
AN - SCOPUS:85197032712
SN - 0026-0495
VL - 158
SP - 155958
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
M1 - 155958
ER -